Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence
Reexamination Certificate
2007-06-15
2011-11-08
Yu, Misook (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
8 to 10 amino acid residues in defined sequence
C435S372000
Reexamination Certificate
active
08053557
ABSTRACT:
It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following:(A) a peptide which consists of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or(B) a peptide which consists of an amino acid sequence comprising a substitution or addition of one or several amino acids with respect to the peptide consisting of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has capacity to induce cytotoxic (killer) T cells.
REFERENCES:
patent: 6794363 (2004-09-01), Bejanin et al.
patent: 7030222 (2006-04-01), Kikuchi et al.
patent: 2006/0204960 (2006-09-01), Nakamura et al.
patent: 2006/0251666 (2006-11-01), Nakatsura et al.
patent: 2008/0044818 (2008-02-01), Nishimura et al.
patent: 2009/0074800 (2009-03-01), Nakatsura et al.
patent: 2009/0111095 (2009-04-01), Nishimura et al.
patent: 2009/0239806 (2009-09-01), Nishimura et al.
patent: 1 813 943 (2007-08-01), None
patent: 2004-303688 (2004-10-01), None
patent: 2006-503575 (2006-02-01), None
patent: WO 0200677 (2002-01-01), None
patent: 2006/043362 (2006-04-01), None
Jones (Pharmacogenomics Journal, 1:126-134, 2001).
Tosatto et al (Current Pharmaceutical Design, 12:2067-2086, 2006).
Elgert et al (Immunology: Understanding the Immune System, 1996, pp. 143-145).
Skolnick et al. (Trends in Biotechnology 2000; 18: 34-39).
Bowie et al. (Science 257: 1306-1310, 1990).
DeGruijl T. D. et al (Nature Medicine, 5(10): 1124-1125, Oct. 1999).
Wang et al. (Exp. Opin. Biol. Ther. 2001; 1 (2): 277-290).
Bodey et al. (Anticancer Research. 2000; 20: 2665-2676).
Boon (Advances in Cancer Research. 1992; 58: 177-210).
Arceci (Journal of Molecular Medicine. 1998; 76: 80-93).
Nakatsura, T. et al., Clin. Cancer Res., 2004, vol. 10, No. 24, p. 8630-8640.
Wang, C.S. et al., Br. J. Cancer, 2004, vol. 91, No. 11, p. 1924-1930.
Ikuta, Y. et al., Clin. Cancer Res., 2005, vol. 11, No. 22, p. 8079-8088.
Komori, H. et al., Clin. Cancer Res., 2006, vol. 12, No. 9, p. 2689-2697.
Akiyama, H. et al., Immunol. Letters, 2002, vol. 83, No. 1, p. 21-30.
Ikuta, Y. et al., “Gan Kogen SPARC o Mochiita Gan Men'eki Ryoho Model no Kakuritsu”, Dai 10 Kai Society for Fundamental Cancer Immunology Sokai Shoroku, Jun. 30, 2006, p. 58, along with an English language translation thereof.
Ikuta, Y. et al., “Gan Tokuiteki ni Kohatsugen suru SPARC o Hyoteki to shita Mouse Gan Men-eki Ryoho Model no Kochiku”, Dai 65 Kai Annual Meeting of the Japan Cancer Association Kiji, Aug. 28, 2006, p. 62 [0-147], along with an English language translation thereof.
Kohler, G. et al., Nature, 1975, vol. 256, No. 551, p. 495-497.
Takahashi, H. et al. Nature, 1990, vol. 344, No. 6269, p. 873-875.
Mouritsen S. et al., J. Immunol., 1992, vol. 148, No. 5, p. 1438-1444.
Ikuta et al., “Identification of the H2-Kd-restricted Cytotoxic T Lymphocyte Epitopes of a Tumor-associated Antigen, SPARC, which can Stimulate Antitumor Immunity without Causing Autoimmune Disease in Mice”Cancer Sci. 100(1):132-137, 2009.
Sangaletti et al., “Leukocyte, Rather than Tumor-produced SPARC, Determines Stroma and Collagen Type IV Deposition in Mammary Carcinoma”J. Exp. Med. 198(10):1475-1485, 2003.
Guweidhi et al., “Osteonectin Influences Growth and Invasion of Pancreatic Cancer Cells”Ann. Surg. 242(2):224-234, 2005.
Ikuta Yoshiaki
Nakatsuru Shuichi
Nishimura Yasuharu
Duffy Brad
Greenblum & Bernstein P.L.C.
Onco Therapy Science, Inc.
Yu Misook
LandOfFree
SPARC-derived tumor rejection antigenic peptides and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with SPARC-derived tumor rejection antigenic peptides and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and SPARC-derived tumor rejection antigenic peptides and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4271646